Innovative therapeutics

RSS Feed

Investors/
Media

Welcome to BioMarin’s Investor Relations & Media Page

We’ve brought together a variety of information in one location to better assist you in your efforts to research and develop news articles and learn about our company.

BioMarin Pharmaceutical Inc. was founded in 1997, and since July 1999 the company's common stock has been traded on the Nasdaq National Market under the ticker symbol BMRN. BioMarin's policy is to fully comply with all rules put forth by the Securities and Exchange Commission and the Nasdaq National Market. For misplaced stock certificates, please contact our transfer agent directly.

Recent News

Email Alerts

Mar 9, 2020

BioMarin's Brinda Balakrishnan, M.D., Ph.D., Honored with 2020 "40 Under 40" Award from the San Francisco Business Times

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Brinda Balakrishnan, M.D., Ph.D., has been named to the San Francisco Business Times 2020 "40 Under 40" list. Now in its ninth year, the

Feb 26, 2020

BioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Results

Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2019 2018 % Change 2019 2018 % Change Total...

Feb 20, 2020

BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) to the FDA for...

Events & Presentations

Cowen 40th Annual Health Care Conference

Tuesday, March 3, 2020

10:40am - 11:10am EST

BioMarin Pharmaceutical Inc. Fourth Quarter and Full Year 2019 Financial Results Conference Call

Wednesday, February 26, 2020

4:30pm - 5:30pm EST